Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O94805

UPID:
ACL6B_HUMAN

ALTERNATIVE NAMES:
53 kDa BRG1-associated factor B; Actin-related protein Baf53b; ArpNalpha; BRG1-associated factor 53B

ALTERNATIVE UPACC:
O94805; A4D2D0; O75421

BACKGROUND:
The Actin-like protein 6B, known for its involvement in chromatin remodeling, is part of the neuron-specific chromatin remodeling complex (nBAF). It plays a significant role in the ATP-dependent remodeling of mononucleosomes, crucial for neural development and dendritic growth. The protein's function in switching the subunit composition of chromatin remodeling complexes is vital for the differentiation of neural progenitors into neurons.

THERAPEUTIC SIGNIFICANCE:
Linked to severe neurodevelopmental disorders, including Developmental and epileptic encephalopathy 76 and Intellectual developmental disorder, Actin-like protein 6B's study offers a promising avenue for therapeutic intervention. Understanding the role of Actin-like protein 6B could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.